gastric juice protein is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-11-14. Where a claim depends on a specific study, the study is described rather than over-claimed.
Most early work on this peptide originated in the 1990s from a research group in Zagreb, Croatia, relying on animal models and cell cultures. Reported observations included effects on gastrointestinal lesion healing, tendon fibroblast migration, and blood vessel formation under controlled laboratory conditions. These findings come predominantly from rodent studies and in vitro assays rather than from human trials. Controlled human data remain limited, and the degree to which animal results translate to human physiology is an open question rather than a settled fact.
Within the research literature, the peptide is discussed through several provisional mechanisms, including cytoprotection, modulation of growth factor signaling, and interaction with the nitric oxide system. None of these mechanisms is fully characterized, and no single pathway is universally accepted. Review articles typically note the gap between consistent animal findings and sparse human evidence. The compound is classified as a research chemical rather than an approved pharmaceutical, which shapes how studies are designed, funded, and reported.
BPC-157 is a synthetic pentadecapeptide with the sequence GEPPPGKPADDAGLV, corresponding to a partial fragment of a larger protein detected in human gastric juice. The name derives from the parent protein designation BPC, an abbreviation of body protection compound, with 157 acting as a fraction or batch identifier used by the original investigators. Its molecular weight is approximately 1419 daltons, and the chain contains no unusual residues or disulfide bridges. In the literature it is described as a short, water-soluble fragment rather than a complete natural protein.
BPC-157 is commonly supplied as a lyophilized powder, a freeze-dried solid that is reconstituted before use in laboratory work. As a short peptide, it dissolves readily in water and in aqueous buffer solutions, and stock solutions are typically prepared in water or a mild buffer. The chain contains several proline and acidic residues, which influence how it behaves in solution. Because the solid can take up moisture, weighing and handling are usually performed under low-humidity conditions. Its solubility class is described as freely soluble in water rather than requiring an organic solvent.
Dry powder is generally stored at low temperature, with minus twenty degrees Celsius or colder advised for extended retention. Reconstituted solutions are less stable than the solid form and are normally kept cold and shielded from repeated freeze-thaw cycles. Light exposure is avoided because some peptides degrade under ultraviolet radiation. The exact rate of degradation depends on concentration, pH, and the presence of salts, so a single shelf life does not apply to every preparation. Reported stability figures should be read as indicative of typical handling rather than as universal constants.
Confirmation of identity and purity relies on standard peptide analysis techniques. Reverse-phase high-performance liquid chromatography separates the peptide from related impurities and serves as the most common purity assay. Mass spectrometry, often coupled to that chromatography step, provides an accurate molecular mass that can be matched against the expected value. Amino acid analysis or sequencing can be added for further confirmation. Because short peptides can be produced by different synthetic routes, laboratories usually report both a chromatographic purity percentage and a mass confirmation rather than a single figure.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C62H98N16O22 | computed for the free peptide |
| Molecular weight | about 1419 Da | monoisotopic mass near 1418.7 |
| Amino acid count | 15 | single chain, no disulfide bonds |
| Solubility | freely soluble in water | also dissolves in saline and phosphate buffer |
| Common synonyms | pentadecapeptide BPC, BPC 157 | fragment notation varies by source |
BPC 157 is a synthetic peptide built from fifteen amino acids. The letters stand for body protection compound, and the number is a laboratory code rather than a description of any biological feature. Its single-letter sequence is GEPPPGKPADDAGLV, which corresponds to a calculated mass near 1419.5 daltons. The material is produced by solid-phase peptide synthesis and is distributed as a lyophilized powder, not as a purified extract from a natural source.
Early work on this family of molecules examined fractions of human gastric juice, where a larger protein was reported to protect gastrointestinal tissue in animal models. BPC 157 was designed as a shorter, more stable fragment of that protein and then studied on its own. The peptide itself is not a normal dietary component and is not present in the human body in meaningful quantities. Descriptions of its origin therefore refer to the research lineage of a laboratory molecule rather than to an endogenous or nutritional substance.
The sequence contains an unusually high proportion of proline and glycine, which limits regular secondary structure and contributes to solubility in aqueous media. The compound dissolves readily in water and in normal saline. Because it is a peptide, digestive enzymes are expected to break it down if it is swallowed, a consideration that influences the routes of administration used in animal experiments. Detailed conformational data remain limited, and published structural models are largely computational.
The molecule carries 15 residues, a molar mass near 1419.5 g/mol, and the formula C62H98N16O22. Its structure features a proline-rich central region, a pair of adjacent aspartic acid residues, and no cysteine. The absence of cysteine means no disulfide bonds can form, which simplifies refolding and reconstitution. Suppliers usually ship the material as a freeze-dried powder that appears white to off-white. It dissolves readily in water and in saline solutions.
Published storage guidance follows general peptide practice rather than product-specific studies. The dry powder is typically kept at minus 20 degrees Celsius, away from light and moisture. Once reconstituted, solutions are generally refrigerated and used over days to weeks, because the aqueous environment slowly promotes hydrolysis and oxidation. Long-term data on degradation rates or breakdown products are sparse. Stated shelf lives from different producers vary widely, reflecting the absence of a shared reference standard.
BPC-157 is normally distributed as a lyophilised powder that ranges from white to off-white in appearance. The peptide dissolves readily in water, normal saline, and common aqueous buffers, and it is poorly soluble in nonpolar solvents such as hexane or vegetable oils. Lyophilised vials take up moisture if left open, which changes the mass of powder in the container and complicates any later weighing. Because the material is handled in small quantities, static and adhesion to glass or plastic can also cause noticeable losses during transfer.
The main chemical liabilities of this sequence are peptide-bond hydrolysis and possible aspartate-related reactions, since the peptide contains aspartic acid residues but no cysteine, methionine, or tryptophan. Absence of those three residues removes the most common oxidation and disulfide pathways from consideration. Studies of related peptides indicate that aspartate isomerisation and aspartimide formation occur most readily at Asp-Gly and Asp-Ala positions, and open questions remain about how quickly those reactions proceed under ordinary laboratory conditions. Storage guidance typically emphasises cool, dry, dark conditions to slow hydrolysis.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry using electrospray or MALDI ionisation. Amino acid analysis and peptide mapping by enzymatic digestion provide additional sequence-level confirmation. Purity is commonly reported as an area percentage from a chromatographic trace, and water content can be measured by Karl Fischer titration. Reported masses may differ by tens of daltons between sources because preparations can contain acetate or trifluoroacetate counterions, and such differences are not by themselves evidence of a different peptide.
On 14 January, the United States Department of Energy announced that the United States had completed their first sales of Venezuelan oil valued at $500 million as part of a $2 billion deal between United States and Venezuela governments. On 15 January, Delcy Rodríguez announced that she was submitting a reform to the country's hydrocarbon law to "allow [foreign] investment flows to be incorporated into new fields, fields where no investment has ever been made and into fields where there is no infrastructure"; On 20 January, Delcy Rodríguez confirmed having received the first $300 million. She announced the money will go to the exchange market in Venezuela, the national banks and the central bank. Reuters indicated that the remaining $200 million were returned on 3 February according to anonymous United States officials. The proceeds from the sales were deposited in a Qatari bank account, preventing Venezuela's creditors from seizing them. Democrats questioned the legality of this arrangement, and criticized the lack of transparency in routing the funds. On 23 January, the first cargo of 460,000 barrels of naphtha by Vitol, necessary to deal with the heavy crude oil, arrived to Venezuela in a deal with the United States. Before that last cargo was received in December 2025 by Chevron Corporation in an agreement with the United States as the naval blockade had stopped many suppliers. On 28 January, Delcy Rodríguez announced that the United States was unfreezing various funds related to 2019 oil sanctions on Venezuela.
AMPylators have been shown to be comparable to kinases due to their ATP hydrolysis activity and reversible transfer of the metabolite to a hydroxyl side chain of the protein substrate. However, AMPylation catalyse a nucleophilic attack on the α-phosphate group, while kinase in the phosphorylation reaction targets γ-phosphate. The nucleophilic attack of AMPylation leads to release Pyrophosphate and the AMP-modified protein are the products of the AMPylation reaction.
In quantum mechanics and quantum field theory, the vacuum is defined as the state (that is, the solution to the equations of the theory) with the lowest possible energy (the ground state of the Hilbert space). In quantum electrodynamics this vacuum is referred to as 'QED vacuum' to distinguish it from the vacuum of quantum chromodynamics, denoted as QCD vacuum. QED vacuum is a state with no matter particles (hence the name), and no photons. As described above, this state is impossible to achieve experimentally. (Even if every matter particle could somehow be removed from a volume, it would be impossible to eliminate all the blackbody photons.) Nonetheless, it provides a good model for realizable vacuum, and agrees with a number of experimental observations as described next. QED vacuum has interesting and complex properties. In QED vacuum, the electric and magnetic fields have zero average values, but their variances are not zero. As a result, QED vacuum contains vacuum fluctuations (virtual particles that hop into and out of existence), and a finite energy called vacuum energy. Vacuum fluctuations are an essential and ubiquitous part of quantum field theory. Some experimentally verified effects of vacuum fluctuations include spontaneous emission and the Lamb shift. Coulomb's law and the electric potential in vacuum near an electric charge are modified. Theoretically, in QCD multiple vacuum states can coexist. The starting and ending of cosmological inflation is thought to have arisen from transitions between different vacuum states.
Sources: en.wikipedia.org
The skin permeability of a compound is based on its physicochemical properties, particularly lipophilicity and hydrophilicity. In general, the more polar groups, for instance hydroxyl groups, that are present in a steroid, and hence the more hydrophilic and less lipophilic it is, the lower its skin permeability. For this reason, progesterone and estrone have higher skin permeability, estradiol has moderate skin permeability, and estriol and cortisol have lower skin permeability. The transdermal bioavailability of progesterone applied to the breasts is approximately 10%. This is roughly the same as that of the general transdermal absorption of estradiol and testosterone, although applied to other skin sites. The site of application of transdermal progesterone may influence its absorption. A study observed a significant increase in circulating levels of progesterone shortly after administration when it was applied as a transdermal ointment to the breasts but not when it was applied to other areas like the thigh or abdomen. Whereas estradiol circulates at levels in the picomolar range (pg/mL), progesterone circulates at concentrations in the nanomolar range (ng/mL), and a relatively large dose is required to produce these levels. The body synthesizes about 25 mg of progesterone per day on average during the luteal phase. This relatively large quantity by weight has been claimed to require around 50% of the body to be used as a surface of absorption to deliver a similar quantity of progesterone on the basis of its absorption mechanics.
=== 25 April === At least 11 people were killed in an RSF drone strike in Atbara that hit a displaced persons camp and energy facilities. RSF shelling from Salha in Omdurman hit the SAF's general headquarters in Khartoum.
Several mutations in Rho proteins have been identified in large scale sequencing of cancers. These mutations are listed in the Catalogue of Somatic Mutations database (http://www.sanger.ac.uk/genetics/CGP/cosmic/). The functional consequences of these mutations are unknown.
Sources: en.wikipedia.org
The sequence corresponds to a fragment of a protein found in human gastric juice, so related sequences are natural. The isolated fifteen-amino-acid peptide supplied for research is produced synthetically. Whether the free fragment circulates naturally in humans has not been settled.
In most jurisdictions it is not an approved medicine and is handled as a research material. Import and sale rules differ by country, and some regulators have placed it in categories that restrict human use. Status can change, so current local rules apply.
Rodent models dominate, particularly rats with induced gastric lesions, tendon injury, or vascular disruption. These designs allow controlled comparison but differ anatomically and metabolically from humans. Results from such models are commonly cited as preliminary.
The lyophilized powder is normally kept at minus twenty degrees Celsius or colder. Solutions are held at refrigerator temperature or below and protected from light. Repeated freezing and thawing is avoided because it can promote aggregation or loss of activity.